Influvac Sub-Unit Tetra

B/Phuket/3073/2013-like virus (B/Phuket/3073/2013, Wild Type) and Influenza Virus B/Austria/1359417/202, the active ingredient in Influvac Sub-Unit Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is intended to prevent influenza infection caused by the specified influenza B virus strains in individuals for whom vaccination is recommended.

GNH USA supplies Influvac Sub-Unit Tetra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Sub-Unit Tetra is used within the influenza vaccine family to protect against specific influenza B virus strains. - Influenza B (B/Phuket/3073/2013-like): Induces protective immunity that reduces the risk of infection and disease severity. - Influenza B (B/Austria/1359417/202): Generates antibodies that help prevent illness caused by this circulating strain. - Seasonal influenza prevention: Contributes to overall seasonal flu control by targeting relevant B‑lineage viruses.

Influvac Sub-Unit Tetra may cause reactions typical of injectable vaccines.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise. - Headache: mild headache within 24 hours. - Myalgia: muscle aches lasting a day or two. - Fatigue: temporary tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder. - Severe allergic reaction: urticaria, bronchospasm, or angioedema. - High fever: temperature > 39°C persisting beyond 48 hours. - Seizures: uncommon in susceptible individuals. - Thrombocytopenia: low platelet count observed rarely.

Before administering Influvac Sub-Unit Tetra, consider the following safety measures. - Allergy assessment: confirm no severe allergy to any vaccine component or previous influenza vaccine reaction. - Immunocompromised patients: evaluate potential reduced immunogenicity and discuss benefits versus risks. - Acute illness: defer vaccination until recovery from moderate or severe acute disease. - Age considerations: follow local guidelines for age‑specific dosing and eligibility. - Concomitant vaccines: separate administration by at least 14 days if using live vaccines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other medical products, requiring attention to timing and patient status.

Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration to reduce risk of interference. - High‑dose immunoglobulin therapy: may neutralise vaccine antigens if given within 2 weeks.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs: may diminish antibody response, consider timing. - Antipyretics: may be used to manage fever but could modestly affect immune response. - Antihistamines: may mask mild allergic reactions, monitor patient closely. - Blood products: transfusions within 48 hours may affect vaccine efficacy.